RP-L102

Rocket Pharmaceuticals Inc. · Phase 2 active Biologic

At a glance

Generic name	RP-L102
Sponsor	Rocket Pharmaceuticals Inc.
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Gene Therapy for Fanconi Anemia, Complementation Group A (PHASE2)
Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A (PHASE2)
A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RP-L102 CI brief — competitive landscape report
RP-L102 updates RSS · CI watch RSS
Rocket Pharmaceuticals Inc. portfolio CI